<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00446589</url>
  </required_header>
  <id_info>
    <org_study_id>47b/31-1-2005</org_study_id>
    <nct_id>NCT00446589</nct_id>
  </id_info>
  <brief_title>The Effects of Ibandronate or Teriparatide Therapy on Bone Histology and Biochemical Indices in Patients on Hemodialysis With Low Bone Mineral Density</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Papageorgiou General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Papageorgiou General Hospital</source>
  <brief_summary>
    <textblock>
      Hemodialysis patients with low bone density (total hip T-score &lt;-2.5) will be assigned to
      receive teriparatide (those with histologic confirmation of adynamic bone disease) or
      ibandronate (subjects with increased osteoclast number on bone biopsy).

      Follow-up period: one year. A second bone biopsy at the end of the study.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    due to financial problems
  </why_stopped>
  <start_date>July 2006</start_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effects of ibandronate and teriparatide on bone mineral density and bone histology in HD patients.</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effects of ibandronate and teriparatide on other bone disease markers</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Osteoporosis</condition>
  <arm_group>
    <arm_group_label>F</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HD pts suffering from osteoporosis and adynamic bone disease who received teriparatide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hemodialysis pts suffering from osteoporosis who received iv ibandronate</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ibandronate</intervention_name>
    <description>iv 1mg ibandronate monthly for one year</description>
    <arm_group_label>I</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>teriparatide</intervention_name>
    <description>sc injection using a pen like device during every hemodialysis session (thrice a week)</description>
    <arm_group_label>F</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Bone mineral density (T-score&lt;-2.5)

          -  Adynamic bone disease for the teriparatide group

          -  Increased osteoclast number on bone biopsy (high turnover) for the ibandronate group

          -  Calcium greater than 8.1 mg/dl

        Exclusion Criteria:

          -  Suspected carcinoma

          -  Unstable clinical setting
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Efstathios Mitsopoulos, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Papageorgiou General Hospital, Thessaloniki, Greece</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Papageorgiou General Hospital</name>
      <address>
        <city>Thessaloniki</city>
        <zip>56403</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 12, 2007</study_first_submitted>
  <study_first_submitted_qc>March 12, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 13, 2007</study_first_posted>
  <last_update_submitted>October 28, 2014</last_update_submitted>
  <last_update_submitted_qc>October 28, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 29, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Papageorgiou General Hospital</investigator_affiliation>
    <investigator_full_name>Efstathios Mitsopoulos</investigator_full_name>
    <investigator_title>Nephrologist</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ibandronic acid</mesh_term>
    <mesh_term>Teriparatide</mesh_term>
    <mesh_term>Diphosphonates</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

